End

Appendicitis: Evolving Tools to Diagnose a Classic Disease

Contributing Editor Appendicitis is a common, potentially lethal condition that affects 7% of individuals sometime in their lives. The condition occurs when the appendix, a blind pouch of intestine at the proximal colon, becomes obstructed by mucus, stool, or lymphatic tissue. Infection ensues, which can rapidly evol...

Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures

EAST HANOVER, N.J.--(BUSINESS WIRE)--Jul 11, 2007 - Since the May2007 release of a New England Journal of Medicine (NEJM) reportthat Avandia users are 43 percent more likely to suffer a heartattack and 67 percent more likely to die of cardiovascular causesthan non-users of Avandia, it is no surprise that physicians intendto switch many type 2 diabetes patients from Avandia to therapiesbelie...

Molecular Target of Bradmer's Neuradiab Further Validated by Independent Findings

TSX: BMR TORONTO, July 10, 2007 /PRNewswire-FirstCall/ - BradmerPharmaceuticals Inc., a biopharmaceutical company dedicated to thedevelopment and commercialization of cancer therapies, todayannounced that new research published by an independent team inBasel, Switzerland validates tenascin as an important moleculartarget for the development of new treatments for glioblastomamultiforme (G...

Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology

WORCESTER, Mass., Jun 27, 2007 (PrimeNewswire via COMTEX NewsNetwork) -- Generex Biotechnology Corporation (Nasdaq:GNBT), theleader in drug delivery for metabolic diseases through the innerlining of the mouth, announced today that it will be making threeposter presentations at the 46th Annual Meeting of the EuropeanSociety of Pediatric Endocrinology in Helsinki, Finland June 27 --30, 200...

Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference

SAN DIEGO--(BUSINESS WIRE)--Jul 2, 2007 - Metabasis Therapeutics(NASDAQ:MBRX), a biopharmaceutical company focused on thediscovery, development and commercialization of novel drugs for thetreatment of metabolic and liver diseases by targeting the liverand liver pathways, announced today that John Beck, senior vicepresident of finance and chief financial officer of Metabasis willpresent at t...

International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis

- ENDORSE Global Findings Highlight the Need to UrgentlyImplement Hospital-Wide Strategies to Optimize VTE Management:Systematically Assess Patient Risk for VTE and Provide Appropriateprophylaxis to Prevent VTE Venous thromboembolism (VTE) risk is high among hospitalpatients and most of these at-risk patients are not pro...

New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility

EXCLAIM is the First International Study to Show That ExtendedThromboprophylaxis Reduces VTE Risk in Acutely-ill Medical PatientsWith a Statistically Significant 44% PARIS, July 8, 2007 /PRNewswire-FirstCall/ --Sanofi-aventisannounced today the results of the EXCLAIM (EXtended CLinicalprophylaxis in Acutely Ill Medical patients) study, which showedthe benefit of extended prophylaxi...

ENDEAVOR IV Clinical Trial Meets Primary Endpoint

MINNEAPOLIS--(BUSINESS WIRE)--Jul 2, 2007 - Medtronic, Inc.,(NYSE:MDT) today announced that a review of data from the ENDEAVORIV Clinical Trial indicates that the trial has met its primary,non-inferiority endpoint. The ENDEAVOR IV Clinical Trial is a randomized, single-blindtrial evaluating the safety and efficacy of the Endeavor(TM) DrugEluting Coronary Stent as compared to the TAXUS Pac...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--June 25, 2007--GileadSciences, Inc. (Nasdaq:GILD) today announced that Study 103, aPhase III clinical trial evaluating the company's once-dailyanti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovirDF) 300 mg as a potential treatment for chronic hepatitis B virus(HBV) infection, met its primary efficacy endpoint. The data showthat Viread...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - GileadSciences, Inc. (Nasdaq:GILD) today announced that Study 103, aPhase III clinical trial evaluating the company's once-dailyanti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovirDF) 300 mg as a potential treatment for chronic hepatitis B virus(HBV) infection, met its primary efficacy endpoint. The data showthat Viread is...

DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

Top Line Data for the Treatment of Type 2 Diabetes Presented at the67th Annual Scientific Sessions of American Diabetes Association SAN FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, Inc., aprivately-held biopharmaceutical company focused on the developmentof therapeutics to treat metabolic diseases, today announced thepresentation of top line data of its phase 2a study of DIO-902, afir...

Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial

CHICAGO, June 21, 2007 /PRNewswire-FirstCall/ -- Advanced LifeSciences Holdings, Inc. , today announced positive results fromTrial CL-06, the first of two pivotal Phase 3 clinical trialsdesigned to assess the safety and effectiveness of cethromycin, anovel once-a-day antibiotic, for the treatment of communityacquired pneumonia (CAP). In the study, cethromycin achievednon-inferiority in i...

Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint

DUBLIN, Ohio--(BUSINESS WIRE)--Jun 20, 2007 - Neoprobe Corporation(OTCBB:NEOP), a diversified developer of innovative oncology andcardiovascular surgical and diagnostic products, today announcedpositive preliminary results from a multicenter Phase 2 clinicalstudy of its lead clinical candidate, Lymphoseek(R) (TechnetiumTc99m DTPA-mannosyl-dextran). Lymphoseek is a proprietaryradioactive tar...

ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting

MONTREAL, June 19 /CNW/ - ConjuChem Biotechnologies (TSX:CJB)today announced that data relating to its proprietaryPC-DAC(TM):Exendin-4 Albumin Conjugate for the treatment ofType 2 diabetes will be presented at the 67th ScientificSessions of the American Diabetes Association (ADA) to beheld June 22-26, 2007 in Chicago, IL. The ADA's annualScientific Sessions meeting is one of the larges...

Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 12, 2007 - CriticalTherapeutics, Inc. (Nasdaq: CRTX) today announced the publicationof data from a pivotal Phase III clinical trial of ZYFLO CR(TM)(zileuton) extended-release tablets in the June 2007 issue of theJournal of Asthma. ZYFLO CR was approved by the U.S. Food and DrugAdministration (FDA) on May 30, 2007. Critical Therapeutics,together with it...

Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today released top-line findingsfrom its six month study of Proellex in the treatment ofendometriosis. This study, conducted in Europe, enrolled 39premenopausal women and has completed six months of dosing. Thestudy included three dose levels of Proellex(TM) as well as apositive control arm. The po...

Medivation's Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimer's Disease Trial After One Year of Therapy

- Aggregate Benefit over Placebo Larger at One Year than at SixMonths - SAN FRANCISCO and WASHINGTON, June 11, 2007/PRNewswire-FirstCall/ -- Medivation, Inc. today announced that thebenefits of Dimebon over placebo in its double-blind,placebo-controlled Phase 2 study in mild-to- moderate Alzheimer'sdisease were statistically significant on all five study endpointsat 12 months. Importantl...

Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 6, 2007 - GileadSciences, Inc. (Nasdaq:GILD) today announced that Study 102, aPhase III clinical trial evaluating the company's once-dailyanti-HIV drug Viread (tenofovir disoproxil fumarate or tenofovirDF) 300 mg as a potential treatment for chronic hepatitis B virus(HBV) infection, met its primary efficacy endpoint. The study showsthat Viread is no...

Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Society's Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Metabasis Therapeutics,Inc. (Nasdaq:MBRX), a biopharmaceutical company focused on thediscovery, development and commercialization of novel drugs for thetreatment of metabolic and liver diseases by applying uniquecapabilities for targeting the liver and liver pathways, announcedtoday that two posters were presented at the Endocrine Society's89th Annu...

Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients

- First Agent Ever to Demonstrate Significant Survival Benefit inLiver Cancer - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- BayerHealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc.today announced that Nexavar(R) (sorafenib) tablets significantlyextended overall survival in patients with hepatocellular carcinoma(HCC), or primary liver cancer versus those taking placebo by 4...

SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial

-- Data Presented at Annual Meeting of the American Society ofClinical Oncology -- SAN MATEO, Calif. -- June 4, 2007 -- SciClone Pharmaceuticals,Inc. (Nasdaq:SCLN) and Sigma-Tau S.p.A today announced thatSciClone's lead product candidate thymalfasin (ZADAXIN(r), thymosinalpha 1) achieved its primary endpoint in a phase 2 clinical trialtreating patients diagnosed with stage IV malig...

MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone

Seven year follow up of pivotal trial confirms that more patientsare alive today due to MabThera BASEL, Switzerland, June 4, 2007-A follow-up analysis trackingthe outcome of patients with aggressive non-Hodgkin's lymphoma(NHL) who were treated with the innovative cancer therapy MabThera(rituximab) over seven years ago has revealed exciting results(1). This analysis of the original...

Waismann Method Survey Reveals Dependency Risk for People Using Suboxone

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--May 31, 2007 - The WaismannMethod today announced findings from an online survey of Suboxoneusers, indicating that 66 percent of individuals currently takingSuboxone, also known as Subutex or Buprenorphine, believe theycannot stop taking the drug without assistance, indicating aphysical dependency. Suboxone is often prescribed to treatdependency to op...

Medicure's MEND-CABG Trial Results Published in Peer Reviewed Journal

WINNIPEG, Manitoba - (May 31, 2007) Medicure Inc. (TSX:MPH;Amex:MCU), a cardiovascular focused biopharmaceutical company,today announced that the results from its Phase 2 MEND-CABG trialare featured in a peer reviewed article in the June edition of TheJournal of Thoracic and Cardiovascular Surgery, published by theAmerican Association of Thoracic Surgery. The article, titled, "Effects of...

New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients

Aggrenox® (Asasantin® Retard) considered by many asfirst-line in secondary stroke prevention INGELHEIM, Germany, 31 May 2007 - New data presented today at the16th European Stroke Conference in Glasgow confirm that therapywith dipyridamole plus ASA (extended-release dipyridamole plus ASAis marketed as Aggrenox® or Asasantin® Retard) is superiorto ASA* alone in...

Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis

FOSTER CITY, Calif.--(BUSINESS WIRE)--May 29, 2007 - GileadSciences, Inc. (Nasdaq:GILD) today announced that its Phase IIIAIR-CF1 (CP-AI-007) study of aztreonam lysine for inhalation forthe treatment of people with cystic fibrosis (CF) who havepulmonary Pseudomonas aeruginosa (P. aeruginosa) met its primaryefficacy endpoint of change at Day 28 from baseline in respiratorysymptoms, as assess...

Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plcannounced today the positive results of studies of theinvestigational medication guanfacine extended release (GXR,previously referred to as SPD503), a selectivealpha-2A-adrenoceptor agonist. These data from two short-term phaseIII placebo-controlled studies and two long-term phase IIIopen-label studies, presented at the 2007 Amer...

Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant

Study shows paroxetine produced no significant drug interactionwith paliperidone ER SAN DIEGO, May 22, 2007 /PRNewswire/ -- After administration ofpaliperidone extended-release (ER) tablets, blood levels of thedrug were not affected when given with a common antidepressant,according to new data presented today at the 160th Annual Meetingof the American Psychiatric Association. Paroxetine,...

New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia

--Study Used To Support FDA Approval of SEROQUEL XR-- WILMINGTON, Del., May 22, 2007 /PRNewswire-FirstCall/ --AstraZeneca today announced that two analyses from a large-scalestudy that investigated the efficacy of SEROQUEL XR(TM) (quetiapinefumarate) Extended-Release Tablets, a once-daily medicine for thetreatment of schizophrenia in adult patients, were presented todayat the annual meeti...

Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Professor IanMeredith, M.D., Monash Medical Centre, Melbourne, Australia, onTuesday presented positive nine-month results from the MedtronicRESOLUTE clinical trial at the EuroPCR meeting in Barcelona, Spain,with data showing a low number of adverse cardiac events and noprotocol-defined stent thrombosis. The next-generation Medtronic(NYSE:MDT...

Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Medtronic(NYSE:MDT) today presented new long-term data from the ENDEAVORclinical trial program reinforcing the existing safety and efficacyprofile of the Endeavor(R) drug-eluting coronary stent system.Four-year results from the 100-patient first-in-man ENDEAVOR Itrial and three-year results from the nearly 1,200 patient ENDEAVORII trial demo...

Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex

MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--May21, 2007 - ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) notesthe publication of new clinical data relevant to the developmentstrategy for Ceflatonin(R) (homoharringtonine). The paper "Targetedtherapy and the T315I mutation in Philadelphia-positive leukemias"by researchers Simona Soverini and colleagues at the University...

Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex

MELBOURNE, Australia, and MENLO PARK, CaliforniaU.S.A. (May 21, 2007): ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ:CXSP) notes the publication of new clinical data relevant to thedevelopment strategy for Ceflatonin® (homoharringtonine). Thepaper "Targeted therapy and the T315I mutation inPhiladelphia-positive leukemias" by researchers Simona Soverini andcolleagues at...

Dendreon Announces Presentation of Data at American Urological Association Annual Meeting

-Data May Support Use of Provenge as Front-line Treatment inAdvanced Prostate Cancer- SEATTLE and ANAHEIM, Calif., May 20, 2007 /PRNewswire-FirstCall/-- Dendreon Corporation today announced the presentation of datafrom an analysis of Phase 3 Studies (D9901 and D9902A) that showeda prolonged survival benefit for patients who were initiallytreated with Provenge (sipuleucel-T) who then went...

Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent

Moffitt Research Presented at 9th International Symposium onMyelodysplastic Syndromes TAMPA, Fla., May 17, 2007 /PRNewswire/ -- New updated resultsfrom a pivotal Phase II trial evaluating Revlimid in patients withan incurable blood cancer known as myelodysplastic syndromes (MDS)were presented today by Dr. Alan List, from the H. Lee MoffittCancer Center & Research Institute, at the 9th...

Positive Statistical Analysis from Synthetic Blood's Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint

COSTA MESA, Calif.--(BUSINESS WIRE)--May 15, 2007 - Synthetic BloodInternational, Inc. (OTCBB:SYBD) today announced positive data froma statistical analysis of its Phase IIa study with Oxycyte(TM) inpatients with traumatic brain injury. In line with preliminarystudy results announced in December 2006, statistical resultsconfirmed that the primary endpoint of increasing patients' oxygentensi...

BDSI Announces Positive Key Secondary Efficacy Endpoint Results for Bema Fentanyl

MORRISVILLE, N.C.--(BUSINESS WIRE)--May 14, 2007 - BioDeliverySciences International, Inc. (Nasdaq: BDSI) announced additionalstatistically significant results with BEMA Fentanyl in cancerpatients with breakthrough pain in its Phase III efficacy clinicaltrial for the product. Results were based on the company's continuing analysis of thesecondary efficacy endpoints from the study. A key s...

GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines

Investigational vaccine could offer protectionfor infants against type b andmeningococcal disease — GlaxoSmithKline (GSK) announced results from aPhase II vaccine clinical study presented this week at thePediatri...

Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke

NICE Appraisal Committee concludes that alteplase is clinicallyand cost effective INGELHEIM/Germany, 14 May 2007 – A new clinical appraisalpublished by the National Institute for Health and ClinicalExcellence (NICE) in the UK has recommended the use of alteplasefor the treatment of patients with acute ischaemic stroke, based onits clinical and cost effectiveness...

Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate Dependency Treatment Are Mothers

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--May 10, 2007 - According toThe Waismann Method 2006 Opiate Dependency Survey 65 percent offemale respondents seeking treatment for opiate dependency have oneor more children. Painkillers such as Vicodin, OxyContin, Percocetand Fentanyl were among the drugs cited. In addition, 35 percent ofthe mothers who reported a dependency said they suffered fromde...